We’re thrilled to welcome Tomi Numminen as the new Chairman of the Board at Biomendex. With nearly 30 years of leadership experience in the medical device and life sciences sectors, Tomi brings a strong track record in guiding innovative companies through commercialization and global growth.

His appointment comes at a pivotal time as we prepare to launch our patented next-generation bone substitute and expand into the global orthopedic market. Our technology—combining biopolymers, bioactive glass, and tricalcium phosphate—has the potential to transform patient outcomes in orthopedic, trauma, and spine surgeries.

At Biomendex, we’re committed to advancing regenerative medicine and setting new standards in bone grafting. With Tomi’s leadership, we’re confident in the road ahead.